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Simulated gastrointestinal digestion of inclusion
complexes based on ovalbumin nanoparticles and
conjugated linoleic acid
Flavia F. Visentini,a,b Joana B. Ferrado,b,c Adrián A. Pereza,b and
Liliana G. Santiago *b
The objective of this work was to obtain and characterize conjugated linoleic acid (CLA) delivery systems
based on ovalbumin nanoparticles (OVAn1 and OVAn2) and to study their behaviour under a standardised
static in vitro digestion model. OVAn1 and OVAn2 were obtained by heat treatment (85 °C, 5 min, pH 11.35
and 7.5, respectively). OVAn1 and OVAn2 had hydrodynamic diameters of 24.63 ± 0.04 and 92.0 ± 0.2 nm,
respectively, showing no significant differences in ζ potential values (p < 0.05) at pH 7.0. CLA nanocom-
plexes were examined in terms of size and ζ potential at pH 3.0 and 7.0, highlighting that binding of CLA
caused an increase in size for OVA and both OVA nanoparticles. Morphological characterization was per-
formed by confocal laser scanning microscopy (CSLM) finding that OVA and OVA nanoparticles had a cir-
cular shape. Also, the CLA encapsulation efficiency (EE) for OVA and OVA nanoparticles was studied, yield-
ing EE values greater than 97% for all systems. Finally, systems were assayed for a standardized in vitro gas-
trointestinal digestion model considering gastric and intestinal steps. Macroscopic appearance, CSLM
images and quantification of CLA retention by HPLC were evaluated after digestion. All the systems
showed the formation of macroscopic aggregates both in gastric and intestinal phases, which generated a
visible precipitate. In all systems, CSLM confirmed the presence of numerous undefined-form aggregates.
Finally, high CLA retention (around 99%) was found for native protein and nanoparticles.
1. Introduction
Conjugated linoleic acid (CLA) is an essential polyunsaturated
fatty acid (PUFA). CLA is the positional and geometric isomer
of linoleic acid (LA, C18:2 cis-9,cis-12), containing a conjugated
double bond system with the bonds separated by a simple
carbon–carbon linkage rather than by the normal methylene
group.1 CLA isomers are produced as intermediates of bio-
hydrogenation of polyunsaturated fatty acids, specifically linoleic
(cis-9, cis-12 C18:2) and α-linolenic (cis-9, cis-12, cis-15 C18:3) by
rumen bacteria, so they are naturally presents in foods derived
from ruminants like meat and milk.2 CLA concentrations in
dairy products typically range from 2.5 to 15.0 mg CLA per g
lipid, of which the cis-9, trans-11 isomer represents the
75–95% of the total CLA.3 CLA has numerous benefits for
human health, including reduction of fat accumulation,4 pre-
vention of cardiovascular diseases,5 it is involved in immune
and inflammatory responses,6 in bone health7 and it has anti-
carcinogenic properties.8
Nevertheless, in general, PUFAs have very low water solubi-
lity and they are susceptible to oxidative deterioration, which
decreases its nutritional value.9 In particular, CLA exhibits very
poor chemical stability showing autoxidation and isomeriza-
tion.10 To overcome these problems, it is necessary to protect/
encapsulate it by using efficient delivery systems. In order to
protect PUFAs against oxidation, different encapsulation
systems have been developed including protein particles,9
micro emulsions,11 liposomes,12 hydrogels13 and systems
based in polymers.14
Food proteins are biopolymers with excellent properties for
encapsulation of bioactive compounds. Usually, food proteins
are GRAS (Generally Recognized as Safe), biodegradable and
biocompatible materials. These are important properties to
promote nutraceutical and pharmaceutical applications. Many
globular proteins have the intrinsic ability to bind lipophilic
compounds9,15–17 and this property could be used as a strategy
to protect and introduce CLA into food matrices. In the last
years, our research team have focused on the evaluation of
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ovalbumin (OVA), the main protein of egg white protein (EWP),
so as to obtain OVA nanoparticles by heat-induced treatment at
different environmental pH conditions. Besides, we have
observed that OVA nanoparticles had an increased capacity to
bind different lipophilic ligands.17,18
In addition, numerous studies show the influence of CLA
on colon cancer.3,16,19 Mixtures of CLA isomers can alter
initiation, promotion, progression and metastasis of malig-
nant tumours through different mechanisms. For example, it
is known that CLA isomers affect lipids metabolisms by inhi-
bition of oxygenase pathway or inducing apoptotic genes
expression.16 A study reported that trans-10, cis-12 CLA isomer
induced apoptosis through reactive oxygen species-mediated
endoplasmic reticulum stress.19
In terms of these evidences, the design of an oral delivery
system for CLA could be a promising tool for colon cancer
treatment. For this, it is essential to know the behaviour of
CLA delivery system under gastrointestinal conditions.
For all the above, the aim of this work was to obtain and
characterize CLA delivery systems and mainly, to study their
behaviour under a standardised static in vitro digestion model.
For this, two nanoparticles were designed based on the OVA
intrinsic ability to bind PUFAs.18,20,21 These systems were
characterized in terms of dynamic light scattering (DLS), con-
focal laser scanning microscopy (CLSM) and encapsulation
efficiency. Finally, in order to get some information about CLA
release/retention from OVA nanoparticle in the gastrointestinal
tract, an examination by applying a standardised static in vitro
digestion model was conducted.22
2. Materials and methods
2.1. Materials
Native ovalbumin (OVA, product A5503, purity 98% according
to agarose gel electrophoresis), conjugated linoleic acid (CLA,
O5507), pepsin from porcine gastric mucosa (P7000), pancrea-
tin from porcine pancreas (P7545), bile extract porcine
(B8631), hemoglobin (H2500) and Nα-p-Tosyl-L-arginine methyl
ester hydrochloride (TAME, T4626) were purchased from
Sigma (USA). These materials were kept according to manufac-
turer advice. Additional analytical reagents were supplied from
Cicarelli (Argentina).
2.2. Nanoparticles formation
It is known that pH is an important variable to obtain heat
induced OVA nanoparticles of different sizes.23 Therefore, in
order to evaluate the influence of particle size on protein nano-
particle digestibility, OVA nanoparticles were produced at two
different pH values. For this, an OVA solution in 50 mM NaCl
was prepared, and pH values were adjusted at 11.4 and 7.5 by
using 1 M NaOH. These protein solutions hydrated overnight
at 4 °C. If it were necessary, pH was readjusted by using 0.1 M
NaOH. Then, aliquots of 2 ml were dispensed in glass tubes,
and they were heated in a water bath at 85 °C over 5 min.
Subsequently, tubes were removed and immediately cooled in
an ice bath. Tubes containing OVA nanoparticles were kept at
4 °C until further analysis. OVA nanoparticle 1 (OVAn1) was pre-
pared at 30 g L−1 OVA and pH 11.4. For OVA nanoparticle 2
(OVAn2), 10 g L
−1 and pH 7.5 were applied.20 It is important to
mention that although the production concentrations of both
nanoparticles were different, OVAn1 and OVAn2 were examined
at the same concentration during the inclusion complexes for-
mation and all the experimental determinations.
2.3. Inclusion complexes formation
Inclusion complexes were produced exploiting the intrinsic
ability of OVA and its nanoparticles to bind lipophilic
compounds.17,18,20,21 In this work, OVA, OVAn1 and OVAn2 solu-
tions in phosphate buffer 50 Mm pH 7.0 were mixed with an
ethanolic solution of 0.1 M CLA to form the inclusion com-
plexes. In order to reach the equilibrium, the protein-CLA
inclusion complexes were left in darkness for 2 h,21 and they
were immediately used.
2.4. Experiment design
In first place, the effect of pH 3.0 and 7.0 on physicochemical
and structural properties of OVA, OVA nanoparticles and OVA
nanoparticles-CLA inclusion complexes were evaluated. For
this, OVA, OVA nanoparticles and protein-CLA inclusion com-
plexes were produced at pH 7.0 and then the pH was lowered
to 3.0 by using 1/0.1 M HCl.
In second place, all systems were evaluated through a simu-
lated gastrointestinal digestion assay consisting of in vitro
gastric and intestinal phases. This assay was divided in two
experiments: (i) SGF without enzymes and SIF without
enzymes and (ii) SGF + enzymes and SIF + enzymes. The aim
of these experiments were to understand if the systems suffer
any physicochemical or structural modification under these
different conditions.
2.5. Physicochemical and structural characterization of
protein-CLA inclusion complexes
2.5.1. Determination of particle size and ζ potential.
Particle size distribution (PSD), polydispersivity index (PdI)
and ζ potential for systems were determined by DLS at 25 °C,
using a Zeta-Sizer (Nano-ZS 90, Malvern Instruments Ltd,
United Kingdom) equipped with a light source at a wavelength
of 632.8 nm and at 90° scattering angle. Particle diameter was
obtained from the peak of the Intensity (%) vs. diameter (nm)
curve (PSDi). PSD in volume (%, PSDv) was also considered in
particle diameter analysis.
2.5.2. Confocal laser scanning microscopy. Rhodamine B
was used to stain the protein-CLA inclusion complexes. For
this purpose, rhodamine B (0.2% w/v) solution was prepared
and it was mixed with inclusion complexes solutions at pH
7.0. These samples were transferred onto a microscope slide,
and they were covered with a cover slip. Images were taken by
using an inverted microscope (Leica TCS SP8, Germany). The
objective used was 63×/NA1.2/Water immersion lens.
Excitation wavelength for rhodamine B was 514 nm. For pro-
cessing images, Fiji software was applied.24
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2.5.3. Determination of encapsulation efficiency. In order
to quantify CLA amount not bound to nanoparticles (free
CLA), OVA nanoparticles (with loaded CLA) were precipitated
by adjusting the pH at 4.8 (OVA isoelectric point) using HCl 1
M.25 Then, a centrifugation step at 10 000g for 20 min was
applied. In order to extract free CLA, supernatants were trans-
ferred to a clean falcon tubes, and they were mixed 1 min in a
vortex with 1 ml hexane. Then, a centrifugation step at 10 000g
for 15 min was applied, and 0.5 ml hexane phase was evapor-
ated under N2 stream. Methanol was added, and resultant
solutions were injected into a chromatographer system consist-
ing of model Prominence Serie 20A (Shimadzu, Japan)
equipped with a manual injector model 7725i (Rheodyne, USA)
and a photodiode array detector model SPD-M20A (Shimadzu,
Japan). CLA content was quantified by RP-HPLC, using a A C18
(ODS) Symmetry300™ column (Waters Corp., USA) of 250 mm
length, 4.6 mm inner diameter, 5 µm particle size and 30 nm
pore size. RP-HPLC experimental conditions were defined
according to Sponton et al.;18 Li et al.26 and Murru et al.27
Separation was performed by means of a linear gradient from
30% water/70% acetonitrile (phase A) to 100% acetonitrile
(phase B) over 15 min. Subsequently, 100% acetonitrile was
maintained over 5 min. Acetic acid solution (0.12 vol%) was
added to both mobile phases, so as to adjust the pH and to
prevent the ion exchange side effect. In all runs, solvent flow rate
was 1 ml min−1. CLA detection was performed at 234 nm wave-
length due to the conjugated diene absorption.28 A calibration
curve for CLA standard in methanol solution (0–150 mg L−1) was
done. From the calibration curve, free CLA concentration were
obtained, and CLA encapsulation efficiency in inclusion com-
plexes (EECLA) was calculated as the ratio between CLA encapsu-
lated amount (in the nanoparticles) and CLA total amount,
EECLA ¼ CLAT  CLAfCLAT  100% ð1Þ
where CLAT is the used amount for the formation of nanocom-
plexes, and CLAf is free CLA amount in the aqueous phase
after encapsulation.
2.6. Simulated gastrointestinal digestion of protein-CLA
complexes and its characterization
2.6.1. Enzymes activity. Pepsin activity was determined as
described by Anson and Mirsky29 and Anson.30 Briefly, 1 ml of
haemoglobin was added into a tube, and it was incubated at
37 °C over 3–4 min. Then, 200 μl of pepsin solution, for each
tested concentration, was added and it was incubated at 37 °C
for 10 min. To stop the reaction, 2 ml of 5% TCA was added into
each tube. To obtain a clear solution, tubes were centrifuged at
6000g over 30 min. The aqueous phase was transferred to a clean
tube, and it was stabilized at 20 °C for few minutes. Finally, the
aqueous phase absorbance was measured at 280 nm and at
20 °C. Blank tubes with the same procedure were made but
adding pepsin (at each tested concentration) after 5% TCA treat-
ment. According to this, pepsin activity was 380 ± 14 U mg−1.
Trypsin activity of pancreatin was measured as described by
Hummel.31 Briefly, spectrophotometer was previously set at
247 nm and at 25 °C. Then, 2.6 ml of 46 mM TRIS/HCl buffer
containing 11.5 mM CaCl2 and 0.3 ml of TAME were directly
added into the measure cuvette, and this one was incubated at
25 °C during 3–4 min. Then, 100 μl of pancreatin, for each
tested concentration, was added. Absorbance at 247 nm and at
25 °C was measured for 10 min. The initial slope from the
linear part of the curve was determined. A blank tube with the
same protocol, but without pancreatin was also realized.
Trypsin activity for pancreatin was 6.9 ± 0.8 U mg−1.
2.6.2. Simulated gastrointestinal digestion assay. A simu-
lation of gastrointestinal process, consisting of in vitro gastric
and intestinal phases, based on an international consensus
method,22 was carried out.
Gastric phase: In this phase, obtained inclusion complexes
were mixed with an equal volume of simulated gastric fluid 1×
(SGF 1×) in two glass tubes with screw caps. SGF 1.25× was pre-
pared as follows: 6.9 mM KCl, 0.9 mM KH2PO4, 25 mM
NaHCO3, 47.2 mM NaCl, 0.1 mM MgCl2, 0.5 mM (NH4)2CO3.
Then, a volume of 0.3 M CaCl2 was added to obtain a final con-
centration of 0.075 mM CaCl2. Afterwards, HCl was used to
adjust the pH at 3.0, then pepsin solution (2000 U ml−1) and
necessary quantity of water was added to obtain 1× SGF. The
tubes were incubated at 37 °C over 2 h under orbital agitation
at 60 rpm (Rotator Multi Bio RS-24, BOECO). Once the reaction
was finished, one of the two tubes continued to the next
phase, while for the other, 2 mM protease inhibitor cocktail
was added.
Intestinal phase: After the gastric phase took place, an equal
volume of simulated intestinal fluid 1× (SIF 1×) was added to
the reaction tube. SIF 1.25× was prepared as follows: 6.8 mM
KCl, 0.8 mM KH2PO4, 85 mM NaHCO3, 38.4 mM NaCl,
0.33 mM MgCl2. Then, CaCl2 to reach a final concentration of
0.3 mM, and a solution of bile salts to reach a final concen-
tration of 10 mM were added. Afterwards, pancreatin solution
previously dissolved in SIF 1.25× (100 U ml−1 based on trypsin
activity) and necessary quantity of water to obtain SIF 1× were
added. After enzyme addition, a spin was performed at 4 °C to
precipitate the insoluble material. Finally, the pH was adjusted
to 7.0. The tubes were incubated at 37 °C for 2 h under orbital
agitation at 60 rpm (Rotator Multi Bio RS-24, BOECO). Once
the reaction was finished, 2 mM of protease inhibitor cocktail
was added.
2.6.3. Determination of CLA retention. Samples of in vitro
gastric and intestinal phases were taken to quantify released
CLA. For this, the extraction and RP-HPLC methods described
in 2.5.3 section were used. From the calibration curve, amount
of released CLA was obtained. Subsequently, the CLA retention
(RCLA) in inclusion nanocomplexes after gastric and intestinal
phases was calculated as follows:
RCLA ¼ CLAe  CLArCLAe  100% ð2Þ
where CLAe is the encapsulated CLA amount in nanocom-
plexes, and CLAr is the released CLA amount from the nano-
complexes after in vitro gastrointestinal digestion.
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2.6.4. Measurement of released soluble peptides. After
in vitro gastrointestinal digestion, the solutions were adjusted
to pH 4.8 to precipitate nanocomplexes and, subsequently,
samples were centrifuged at 10 000g for 20 min. The amount
of soluble peptides in supernatant was measured at 280 nm by
using a UV visible spectrophotometer (Jenway 7305, UK).32 For
this experiment, SGF 1× and SIF 1× were used as blanks.
2.6.5. Confocal laser scanning microscopy. Rhodamine B
was used to stain the inclusion nanocomplexes previous to the
in vitro gastrointestinal digestion procedure.33 Experiment
were conducted as it was described in 2.5.2 section.
2.7. Statistical analysis
All assays were performed in triplicate at room temperature,
unless otherwise stated. Means and standard deviations were cal-
culated from these measurements. Differences between means
were determined according to LSD test at 95% significance level
(p < 0.05) by using Stat Graphics Centurion XV software.
3. Results and discussion
3.1. Physicochemical and structural characterization of
protein-CLA inclusion complexes
3.1.1. Size and ζ potential. It is known that heat treatment
induces the formation of OVA aggregates, which show confor-
mational characteristics dependent on the process conditions,
such as pH, temperature and ionic strength.34,35 Moreover, it
was documented that the formation of disulphide bonds
and hydrophobic interactions are relevant for aggregates
formation.36,37
Colloidal behavior of inclusion nanocomplexes under
in vitro gastrointestinal digestion constitutes an essential
knowledge to formulate new functional foods.38,39 In this
sense, digestion occurs mainly in stomach (gastric phase) at
mean pH of 3.0 and in small intestine at mean pH of 7.0. So,
the effect of pH (3.0 and 7.0) and CLA binding on size and
electrical properties of OVA, OVAn1 and OVAn2 are presented in
Fig. 1 and Table 1. Fig. 1 shows the PSDi for OVA and OVA-CLA
at pH 7.0 (A) and at pH 3.0 (B); for OVAn1 and OVAn1-CLA at pH
7.0 (C) and at pH 3.0 (D) and for OVAn2 and OVAn2-CLA at pH
7.0 (E) and at pH 3.0 (F). As it can be deduced from Table 1, at
pH 7.0, CLA formed supramolecular structures with hydrodyn-
amic diameter (dH) of 289 ± 3 nm (99.5 ± 0.7% in volume) and
ζ potential of −57 ± 9 mV, indicating the formation of CLA
stable colloidal suspensions. Nevertheless, at pH 3.0, there was
a considerable increase in dH, 2117 ± 201 nm. This could be
explained considering that pH 3.0 is close to pKa of carboxylic
group of fatty acids and, therefore, the charge and electrostatic
repulsions could decrease, allowing the formation of larger
structures. This explanation is in agreement with ζ potential
value found of 0 ± 1 mV. It is important to mention that after
24 h no precipitates were observed, indicating that CLA supra-
molecular structures formed at pH 7.0 and 3.0 were colloidally
stable. When PUFA concentration exceeds a critical value in
aqueous solution, known as critical micelle concentration
(CMC), fatty acids usually self-assemble to form supramolecular
structures (e.g. micelles and vesicles), which confer turbidity to
the solution.8,40,41 This phenomenon occurs because fatty acid
molecules associate with tails arrange to each other inner while
heads remain outside in contact with water molecules, so the
particle size is in the same order of light wavelength.42
DLS measurements for OVA presented two peaks in PSDi
(also in PSDv), both at pH 7.0 and 3.0 (Fig. 1). The first peak at
12 ± 2 nm (97.5%) and at 10.3 ± 0.4 nm (97%), and the second
one at 62 ± 3 nm (2.5%) and at 58 ± 3 nm (3%), respectively.
Kang et al.43 reported that no conformational changes in the
second and tertiary OVA structure were registered under pH
changes. Hence, in general terms, it could conclude that the
first peaks observed for both pH values (7.0 and 3.0) would
correspond to OVA dH, and the second ones to traces of some
aggregated protein. Nevertheless, at pH 7.0, OVA-CLA com-
plexes showed two main peaks: at 93 ± 18 nm (44%) and at
288 ± 8 nm (55%) (Table 1; Fig. 1A). So, it could be deduced that
smaller peak corresponds to the formation of inclusion com-
plexes based on CLA and OVA, and larger one to CLA supra-
molecular structures (i.e. CLA not bound to native protein).
The OVA ζ potential value was −15 ± 2 mV, due to the negative
charge of carboxyl groups, whereas the complex formation
caused a decrease in ζ potential to −26 ± 2 mV. The decrease
in ζ potential value could be explained by the formation of
inclusion nanocomplexes. The ζ potential can be modified by
the adsorption of charged species such as ions and ionic sur-
factants on particle surface.44 CLA molecules have an aliphatic
chain (apolar tail) at one end and a carboxylic group (polar
head) at the other. Therefore, if CLA is bound to OVA through
hydrophobic interactions by means of its aliphatic chain, the
ionized polar head would be oriented outside onto the protein
surface in contact with aqueous medium increasing the nega-
tive charge of OVA.20
In addition, PSDi for OVA-CLA nanocomplex at pH 3.0, was
similar to the one observed at pH 7.0, showing two peaks: at
44 ± 4 nm (23%) and at 207 ± 14 nm (75%) (Table 1; Fig. 1B).
The ζ potential for OVA at pH 3.0 was 19 ± 1 mV, due to the
presence of protonated amino groups on the protein, while for
OVA-CLA nanocomplex was 10.0 ± 0.5 mV. This could be
explained considering that CLA had a slight negative charge, and
under binding to OVA, the nanocomplex ζ potential decreased.
For OVAn1 at pH 7.0, dH was 24.63 ± 0.04 nm (100%), while
for OVAn1-CLA inclusion complex two peaks were registered: at
28.79 ± 0.05 (99.8%) and at 224 ± 24 (0.2%) nm (Table 1;
Fig. 1C). As it can be noted, the binding of CLA produced an
increase in OVAn1 size (p < 0.05), and almost all the nano-
particles volume would correspond to the presence of nano-
complexes, so the amount of free PUFA could be negligible.
The ζ potential value for OVAn1 was −15.9 ± 0.1 mV.
Complexation between OVAn1 and CLA produced a decrease of
ζ potential value to −28 ± 1 mV. These results were consistent
with the ones obtained for OVA-CLA inclusion complex.
At pH 3.0, PSDi and PSDv for OVAn1 showed a dH of 23.1 ±
0.8 nm (100%) and no significant difference (p > 0.05) in com-
parison with pH 7.0 was found. Meanwhile for the OVAn1-CLA
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nanocomplex, only one peak was detected at 231 ± 2 nm
(100%) (Table 1; Fig. 1D). In addition, OVAn1-CLA nanocomplex
solution presented a slight turbidity, which could be due to
the nanocomplex size is in the order of light wavelength.42
OVAn1 had a ζ potential value of 15.2 ± 0.6 mV, whereas the
OVAn1-CLA nanocomplex formation produced an increase in
the ζ potential value to 26 ± 1 mV.
For OVAn2 at pH 7.0, two peaks at 92.0 ± 0.2 nm (98.2%)
and at 16 ± 2 nm (1.7%) were registered, being the first one
representative of the protein nanoparticle. In addition, for
OVAn2-CLA complex, also two peaks appeared at 237 ± 43 nm
(83%) and at 31 ± 20 nm (16%) (Table 1; Fig. 1E). The binding
of CLA produced an increase in OVAn2 size indicating the
nanocomplex formation. The ζ potential value for this nano-
particle was −15 ± 2 mV, and for OVAn2-CLA nanocomplex was
−19.4 ± 0.3 mV.
At pH 3.0, the OVAn2 had a dH of 103 ± 1 nm (98%) (Table 1;
Fig. 1F), and no significant difference with pH 7.0 was found
(p > 0.05). Nevertheless, the dH for OVAn2-CLA system cannot
be determined due to the precipitate formation (Insert in
Fig. 1F). This phenomenon might be due to the formation of
big nanocomplex aggregates that precipitate as a consequence
of gravitational force. The ζ potential value for OVAn2 and
OVAn2-CLA nanocomplex were 14.7 ± 0.3 mV and 13.9 ±
0.4 mV, respectively, indicating that pH 3.0 had no influence
on the ζ potential values (p > 0.05).
In summary, ζ potentials values did not show significant
differences (p > 0.05) for OVA and OVA nanoparticles at pH 7.0,
Fig. 1 Particle size distribution (PSD) based on Intensity percentage (%) for OVA (–), OVA-CLA ( ) at pH 7.0 (A) and pH 3.0 (B); OVAn1 (–), OVAn1-CLA
( ) at pH 7.0 (C) and pH 3.0 (D) and OVAn2 (–), OVAn2-CLA ( ) at pH 7.0 (E) and pH 3.0 (F; the tube photo shows the aspect of OVAn2-CLA precipitate).
Conditions: Protein concentration: 23 µM, PUFA concentration: 1 mM, temperature: 25 °C.
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and they were statistically similar at pH 3.0, suggesting that
heat treatment and pH had little influence on the protein net
charge. In the same way, there were not significant differences
among the sizes of OVA, OVAn1 and OVAn2 both at pH 3.0 and
at pH 7.0. On the other hand, the increase in particle size for
all systems with CLA indicated the formation of protein-CLA
inclusion nanocomplexes.
3.1.2. Confocal laser scanning microscopy. Fig. 2 shows
CSLM for OVA-CLA (A), OVAn1-CLA (B) and OVAn2-CLA (C)
stained with rhodamine B. For the three nanocomplexes, a cir-
cular shape was observed and the sizes were in agreement with
the ones reported in previous section. Firstly, for OVA-CLA
nanocomplex (Fig. 2A), the size was very small and only one
population could be identified. Nevertheless, for both nano-
particles, two populations could be seen: one corresponding to
size around 25 nm for OVAn1-CLA system (Fig. 2B) or around to
90 nm for OVAn2-CLA system (Fig. 2C), and another population
with minor size that could correspond to a fraction of not
aggregated OVA. CLSM images indicated that OVA or OVA nano-
particles were evenly distributed throughout the colloidal solu-
tion samples, i.e., extensive particle aggregation was not evi-
denced (Fig. 2).
3.1.3. Encapsulation efficiency. The percentage of encapsu-
lated (loaded) CLA (EECLA) in OVA, OVAn1 and OVAn2 are shown
in Fig. 3. Both nanoparticles had slightly higher (p < 0.05)
EECLA values than the one observed for OVA (99% against 97%,
respectively). However, there was no significant differences in
EECLA values between both nanoparticles (p > 0.05), highlight-
ing that particle size had no influence on encapsulated CLA.
3.2. In vitro gastrointestinal digestion of OVA-CLA inclusion
complexes and their characterization
3.2.1. Macroscopic appearance. Fig. 4 shows the macro-
scopic appearance of OVA-CLA, OVAn1-CLA and OVAn2-CLA
Table 1 Effect of protein-CLA complexation on hydrodynamic dia-
meter (nm), volume (%) and zeta potential (ζ, mV) of OVA, OVAn1 and
OVAn2 as a function of aqueous medium pH. Conditions: Protein con-
centration: 23 µM, CLA concentration: 1 mM, temperature: 25 °C. The
ANOVA for hydrodynamic diameter was performed for each system (e.g.
OVA and OVA-CLA at pH 7.0 and 3.0). The ANOVA for ζ potential was
made for all systems together. Values are showed as mean ± standard
deviation and different letters indicate statistical differences (p < 0.05)
System pH Diameter (nm) Volume (%) Zeta potential (mV)
CLA 7 289 ± 3a 99.5 ± 0.7 −57 ± 9a
3 2117 ± 201b 100 0 ± 1e
OVA 7 12 ± 2a 97.5 ± 0.4 −15 ± 2d
62 ± 3c 2.5 ± 0.4
3 10.3 ± 0.4a 97.15 ± 0.07 19 ± 1h
58 ± 3c 2.85 ± 0.07
OVA-CLA 7 93 ± 18d 44 ± 11 −26 ± 2b
288 ± 8f 55 ± 11
3 44 ± 4b 23.4 ± 0.1 10.0 ± 0.5f
207 ± 14e 74.9 ± 0.4
OVAn1 7 24.63 ± 0.04
a 100 −15.9 ± 0.1d
3 23.1 ± 0.8a 100 15.2 ± 0.6g
OVAn1-CLA 7 28.79 ± 0.05
b 99.8 ± 0.07 −28 ± 1b
224 ± 24c 0.2 ± 0.07
3 231 ± 2c 100 26.2 ± 1.5i
OVAn2 7 92.0 ± 0.2
b 98.2 ± 0.9 −15 ± 2d
16 ± 2a 1.7 ± 0.9
3 103 ± 1b 98 ± 2 14.7 ± 0.3g
21.22 ± 2a 2 ± 2
OVAn2-CLA 7 237 ± 43
c 83 ± 5 −19.4 ± 0.3c
31 ± 20a 16 ± 5
3 Precipitation 13.9 ± 0.4g
Fig. 2 Confocal laser scanning microscopy (CSLM) of OVA-CLA (A),
OVAn1-CLA (B) and OVAn2-CLA (C) stained with rhodamine B. The thick
border box shows a zoom of the thin border box (zoom factor: 3).
Objective used was 63×.
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nanocomplexes under in vitro gastrointestinal digestion. In
first place, the systems were assayed to gastric and intestinal
phases, but only with SGF (without pepsin) and SIF (without
pancreatin and bile salts) for 2 h at 37 °C under orbital agita-
tion at corresponding pHs (i.e. 3 and 7). The aim of this assay
was to study the influence of pH and salt composition of simu-
lated fluids on visual aspects and CLA retention of inclusion
nanocomplexes. As it can be seen, systems presented turbidity
and the presence of small particles both, in SGF and SIF for
OVA-CLA, OVAn1-CLA and OVAn2-CLA systems. In order to
understand what happened, it is necessary to analyze the vari-
ables of the in vitro digestion protocol such as agitation, temp-
erature and presence of salts. All solutions were subjected to
orbital agitation at 60 rpm, heat at 37 °C and salts addition (as
CaCl2) over 2 h. It is known that proteins denature and aggre-
gate by shaking, and OVA is very sensible to agitation.45–47 In
addition, there is evidence that Ca2+ (as CaCl2) accelerate pro-
teins aggregation, in general,48,49 and the OVA one, in particu-
lar.50 Cheng et al.51 studied digestion of zein nanoparticles
and when they were subjected to SGF, a precipitation phenom-
enon was observed. Authors explained that added ions
increased both the amount of non-dispersed protein and the
tendency of particles to self-assemble into larger structures.
Although for most of nanoparticles, the conditions used were
more extreme than those used in the in vitro digestion proto-
col, the combination of all factors for a prolonged period were
applied in this assay. This combination could explain the
macroscopic appearance of aggregates in the systems, when
they were subjected to SGF. In SIF, small particles in suspen-
sions and less turbidity were evidenced, which could suggest
that aggregates formed under gastric conditions remained
Fig. 3 Encapsulation efficiency of CLA (%) for OVA, OVAn1 and OVAn2,
expressed as percentage. Different letters indicate statistical differences.
Fig. 4 Photographs of the macroscopic appearance of the different systems (OVA-CLA, OVAn1-CLA and OVAn2-CLA) when they are subjected to an
in vitro gastrointestinal digestion. SGF/SIF column: the systems were subjected to an in vitro digestion without enzymes. Left photo corresponds to
gastric phase and right photo corresponds to intestinal phase. SGF + pepsin/SIF + pancreatin column: the systems were subjected to an in vitro
digestion with enzymes. Left photo corresponds to gastric phase and right photo corresponds to intestinal phase. SIF + pancreatin + bile salt
column: the systems were subjected to an in vitro digestion with enzymes and bile salt in the intestinal phase.
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intact in the intestine. It is necessary to mention that all the
systems precipitated after a few hours resting.
In other assay, systems were subjected to in vitro digestion
with enzymes. For SGF, pepsin was added at 2000 U ml−1 final
activity, and for SIF, pancreatin was added at 100 U ml−1
(ref. 22) final activity. At the same time, so as to complete the
in vitro model, systems were subjected to an intestinal phase
under presence of pancreatin and bile salts. As it was noted
before, all systems showed turbidity and small particles in
suspension, both in gastric and intestinal phases. Particle
sizes could not be determined due to the presence of nano-
particles precipitated in all systems. The presence of enzymes
seemed to have no influence on macroscopic appearance.
In SGF + pepsin systems, the presence of particles in sus-
pension could indicate that the aggregates formed under con-
ditions discussed above were not hydrolyzed by pepsin, or if
they were hydrolyzed, the resulting peptides could aggregate
due to gastric conditions. Martos et al.52 studied OVA digestion
and they discovered that it was very resistant to pepsin action
at pH values around 2.0. OVA adopts a molten globule state
maintaining a high degree of conformational stability and
resisting pepsin action. The degree of enzymatic hydrolysis
depends on heating conditions used during nanoparticles for-
mation and on its morphology, since this might cause that the
cleavage sites were more or less exposed to pepsin.53,54 On the
other side, aggregation could protect OVA nanoparticles from
enzymatic cleavage. In this sense, Del Castillo-Santaela et al.
(2016) found that when human serum albumin is crosslinked
with glutaraldehyde, the formation of large aggregates makes
the system very resistant to pepsin action.54 Pepsin is a water-
soluble enzyme and its activity is limited if peptide-substrates
are not well dispersed in the media.51
In SIF + pancreatin systems, OVAn2-CLA system had greater
turbidity and precipitated immediately, whereas OVA-CLA and
OVAn1-CLA samples required more time to precipitate. In pres-
ence of bile salts, the behavior was the same, but a yellow
color (own of bile salts) was observed. Nyemb et al.53 reported
that only 37% of OVA resisted to pancreatin digestion, and
only 30% of agglomerated OVA resisted intestinal digestion.
Complementary studies would be required to determine if
nanoparticles remain intact forming aggregates or if they
break into peptides. In this sense, Chen et al.,55 found that soy
protein isolate nanoparticles loaded with curcumin formed
aggregates when they were subjected to an in vitro gastrointes-
tinal digestion. In SGF and SIF the nanoparticles aggregation
was attributed to protein hydrolysis that could promote the
exposure of protein hydrophobic clusters towards the aqueous
phase, or the release of hydrophobic peptides able to promote
aggregation.
3.2.2. CLA retention. The CLA retention (RCLA) after in vitro
gastrointestinal digestion was evaluated for OVA, OVAn1 and
OVAn2 systems (Table 2). In first place, RCLA was calculated for
systems subjected to gastric phase without enzymes. As it
could be observed, there was no significant differences among
the RCLA for OVA and for both OVA nanoparticles (p > 0.05).
When pepsin was added, the RCLA decreased significantly (p <
0.05) respect to gastric phase without enzymes for OVA-CLA
and OVAn2-CLA systems. The RCLA values for OVAn1 and OVAn2
systems were high. These results were consistent with the pres-
ence of dispersed particles, since if proteins were not hydro-
lysed, they could retain most of the encapsulated CLA.
Fig. 5 Absorbance at 280 nm as a measure of released peptides from
OVA-CLA, OVAn1-CLA and OVAn2-CLA after gastric ( , pepsin) or intesti-
nal ( , pancreatin and bile salts) in vitro digestion. Different letters indi-
cate statistical differences.
Table 2 Retained percentage of CLA in OVA, OVAn1 and OVAn2 after in vitro gastrointestinal digestion. Gastric: SGF row: represent the retained per-
centage of CLA when the system is summited to an in vitro digestion without enzymes. Gastric: SGF + pepsin row: represent the retained percentage
of CLA when the system is summited to an in vitro digestion with pepsin. Intestine: SIF row: represent the retained percentage of CLA when the
system is summited to an in vitro digestion without enzymes. Intestine: SIF + pancreatin row: represent the retained percentage of CLA when the
system is summited to an in vitro digestion with pancreatin. Intestine: SIF + pancreatin + bile salt row: represent the retained percentage of CLA
when the system is summited to an in vitro digestion with pancreatin and bile salt. Different letters indicate statistical differences (p < 0.05)
Percentage of retained CLA (%)
OVA-CLA OVAn1-CLA OVAn2-CLA
Gastric: SGF 99.5 ± 0.1c 99.6 ± 0.1c 99.6 ± 0.1c
Gastric: SGF + pepsin 82 ± 2a 98.9 ± 0.2c 96.2 ± 0.7b
Intestine: SIF 99.4 ± 0.1c 99.5 ± 0.1c 99.5 ± 0.1c
Intestine: SIF + pancreatin 99.5 ± 0.1c 98.7 ± 0.2c 99.3 ± 0.2c
Intestine: SIF + pancreatin + bile salt 99.3 ± 0.2c 99.3 ± 0.2c 99 ± 1c
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Moreover, if hydrolysis occurs, possibly the resulting peptides
could retain the ability to bind CLA.51 OVA retained CLA in
minor proportion compared with both nanoparticles (p <
0.05). Besides, OVAn1 retained slightly higher amount of CLA
than OVAn2 sample (p < 0.05) after SGF.
After gastric phase, the systems were subjected to SIF phase
without enzymes to evaluate how intestinal condition influ-
enced on retained CLA. As it was discussed before, there were
not statistical differences in RCLA among OVA, OVAn1 and
OVAn2 samples. In addition, these values were not different
Fig. 6 Confocal Laser Scanning microscopy (CSLM) of OVA-CLA (A, B), OVAn1-CLA (C, D) and OVAn2-CLA (E, F) stained with rhodamine B after
in vitro gastrointestinal digestion. SGF: systems were summited a simulated gastric fluid containing pepsin. SIF: systems were summited a simulated
intestinal fluid containing pancreatin and bile salts. The thick border box shows a zoom of the thin border box (zoom factor: 3). Objective used: 63×.
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that the ones obtained for SGF without enzymes. This could
suggest that protein aggregates formed under gastric condition
remained intact after intestinal conditions. On the other hand,
when systems were digested under SIF + pancreatin or SIF +
pancreatin + bile salts, no statistical differences in RCLA among
OVA, OVAn1 or OVAn2 samples (p > 0.05) were found, and the
values were around 99%. The RCLA values in intestinal phase
were the same or superior (in the case of OVA) in comparison
with gastric phase. This result could be explained assuming
that the aggregates formed in the gastric phase at pH 3.0 could
remain intact, and the pancreatin in intestine could not be
able to break them.
3.2.3. Released soluble peptides. In order to confirm pre-
vious results, peptides released from proteins after simulated
digestion were spectroscopically determined by means of
absorbance at 280 nm (Fig. 5).32 In SGF, the released peptides
amount was higher than the ones registered in SIF for all
systems. OVA-CLA system in SGF released a greater amount of
peptides than when CLA is bound to both OVA nanoparticles
(p < 0.05). These results could be explained considering that
protein aggregation and further complexation with CLA might
have promote enzymes cleavage sites occlusion. On the
other hand, there was no significant difference in the released
peptides amount for OVA or OVA nanoparticles in SIF
(p > 0.05).
3.2.4. Confocal laser scanning microscopy. All systems
were stained with rhodamine B and they were assayed by
CSLM (Fig. 6). Images for OVA-CLA system in SGF + pepsin
(Fig. 6A) showed big amorphous aggregates and others small
and spherical structures. In SIF + pancreatin (Fig. 6B), it could
be observed bigger spherical aggregates. For OVAn1-CLA and
OVAn2-CLA systems in SGF + pepsin (Fig. 6C and E, respect-
ively) and in SIF + pancreatin (Fig. 6D and F, respectively) big
amorphous aggregates were observed. These results are in
agreement with the precipitation behavior (Fig. 4), that might
be promoted by the observed aggregates. On the other side, it
can be hypothesized that assembly of individual nanoparticles
could form aggregates. This observation could confirm that
nanoparticles aggregate at pH 3.0 and did not dissolved or
enzymes attacked them. CLA could be strongly retained in
nanoparticles due to the formation of these big aggregates. As
it was mentioned before, a complementary study would be
required to confirm if the nanoparticles remain intact forming
aggregates or if they break into peptides that subsequently
aggregate.
4. Conclusions
In the present work, two nanoparticles and their CLA inclusion
nanocomplexes were obtained and characterized in terms of
particle size, electrical properties and morphological aspects.
Complexation among OVA/OVA nanoparticles with CLA showed
an increase in particle size, furthermore CLSM confirmed a
rounded shape for inclusion nanocomplexes. The efficiency of
OVA, OVAn1 and OVAn2 to encapsulate CLA were superior to
97%. Finally, the nanocomplexes were subjected to an in vitro
gastrointestinal digestion. Macroscopic appearance of all
systems showed the presence of protein aggregates and dis-
persed particles which subsequently precipitated after a
resting time. For all systems, CLSM images highlighted the
presence of amorphous aggregates. For OVA and both nano-
particles, great CLA retention was obtained after enzyme diges-
tion in gastric and intestinal phases. The results obtained in
this paper would suggest that these inclusion nanocomplexes
could be applied as promising oral delivery systems for CLA
and other lipophilic drugs at gastrointestinal tract. The greater
gastrointestinal retention showed by this system could be
exploited in the design of new functional foods for prevention/
treatment of colon cancer. In a future contribution, this issue
will be addressed.
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